Maintain current weight; do not increase exposure; trim 10-15% into strength at $90-$91; full reassessment to underweight on close below $85.50 on rising volume.

• Q2 benefited from earlier-than-expected EM pricing, favorable commodity hedging windows, and easy comps—annualizing one quarter to ~$4 EPS power ($13.38B run rate) is an extrapolation trap that ignores the durability question
• Forward P/E at $4 EPS would be 22x—still rich versus KO's historical 22-24x range; the multiple compresses when rates stay high
• MACD collapsed 86% from 1.88 to 0.26 in three weeks; histogram crossed negative for first time since July 2024—acting before breakdown rather than after is the conservative discipline
• KO fell 25% in 2022 from $71 to $51; institutional buyers stepped in when earnings yield blew out to 5%+ against 10-year at 4%; today earnings yield is 3.8% with 10-year above 4%—that support floor isn't present
• 200 SMA at $79 represents an 11% downside; VWMA rolling over from $89 to $87.96; KO underperforming the tape on up days suggests soft distribution forming
• From late 2021 through 2023, KO's P/E compressed ~27% from 30x to 22x even though earnings held—rising discount rates compressed present value despite solid fundamentals
• Current regime is 96% no-cut probability; KO trades at 26.6x trailing multiple with 27% compression risk to 22x (~$78) if rates remain elevated
• KO is up ~35% TTM while PEP is at 52-week lows; the relative-value trade has played; mean reversion in the ratio is the more likely next move
• Howard Buffett position retention doesn't generate the same multiple-expansion flow as Berkshire ownership—the 'Buffett cult premium' as a marginal bid driver is gone
• Trading at 96% of 52-week high with stretched valuation (26.6x), deteriorating momentum, and 50 SMA tested three times in two weeks—trimming into strength is rebalancing discipline, not leaving money on the table

→ vs aggressive: Q2 $13.38B run rate annualized to ~$4 EPS is not 'stale'—it's an extrapolation trap; even at $4 EPS, 22x forward remains rich versus KO's 22-24x historical range

→ vs aggressive: MACD 'reset' from 1.88 to 0.26 (86% collapse in three weeks) with histogram crossing negative for first time since July is not just a reset—conservative discipline acts before breakdown, not after confirmation

→ vs aggressive: 0.34 beta provides smaller amplitude drawdowns, not immunity; earnings yield of 3.8% vs 10-year above 4% means the $51 institutional bid floor from 2022 isn't present today; 200 SMA at $79 is 11% away

→ vs aggressive: Defensive rotation benefit is 'half right'—KO's P/E compressed 27% from ~30x to 22x from late 2021 through 2023 despite solid fundamentals; at 26.6x trailing, rate compression risk is live with KO at 22x (~$78) as realistic floor

→ vs aggressive: PEP share transfer tailwind is largely in the price; KO up 35% TTM while PEP at 52-week lows; mean reversion in the ratio is the more likely next move, not further KO outperformance

→ vs aggressive: Howard Buffett retention doesn't replicate Berkshire's multiple-expansion flow; the 'Buffett cult premium' as a marginal bid driver is gone even if the position stays

→ vs aggressive: Adding into a bearish MACD crossover with negative histogram—regardless of 50 SMA holding—is averaging into a deteriorating setup; if 50 SMA fails on rising volume, the result is a 15% drawdown instead of a 10% drawdown with a stop that provides exit

HOLD; maintain current weight without increasing exposure; soften trim to 5-7% only on confirmed breakout above $90 with RSI above 60; condition tactical add at 50 SMA on momentum confirmation; keep $85.50 stop loss and $92 breakout trigger unchanged

• Q2 2026 data shows 6.7% top-line acceleration and 16% net income growth, representing structural franchise pricing power, not a one-quarter fluke
• Annualizing Q2 to $4 EPS power and dismissing the PEG is extrapolation—the 22x forward multiple remains within the 22-24 historical band
• KO's 0.34 beta makes the conservative's 1-2 risk-reward asymmetry framework inappropriate; the asset is a low-beta compounder, not a cyclical or momentum name
• The 27% multiple compression scenario (KO to ~$78 at 22x) is a tail risk, not base case—Polymarket's 96% no-cut probability largely prices in the hawkish hold
• Three 50 SMA tests in two weeks indicates weakening structural support, not bullish consolidation—86% MACD collapse and first negative histogram since July are real warnings
• The PEG ratio of 3.96 is genuinely elevated at consensus 5.9% growth, even if EPS lands at $4; full valuation caps re-rating potential
• Polymarket's 96% no-cut probability suggests marginal rate news is more likely dovish than hawkish—a mild tailwind for KO the conservative underweights
• Thirty-five percent TTM run warrants banking some gains but not treating KO like a momentum stock requiring 10-15% trim; trim of 5-7% max on confirmed breakout is appropriate

→ vs aggressive: Annualizing Q2 to $4 EPS to dismiss the PEG is hopefulness, not analysis; the 22x forward multiple remains within the 22-24 historical band and the Street hasn't revised because durability isn't proven

→ vs aggressive: Three 50 SMA tests in 14 days is deteriorating momentum, not bullish consolidation; negative MACD histogram for the first time since July is a warning that demands discipline, not aggression

→ vs aggressive: Adding at the 50 SMA without momentum confirmation is skipping the conditionality that distinguishes a high-conviction setup from a level test

→ vs conservative: The 1-2 risk-reward asymmetry only applies to high-beta names; KO's 0.34 beta means drawdowns are bought by yield-driven institutional flows and the earnings yield beats the 10-year

→ vs conservative: Treating the 27% compression scenario as base case rather than tail case underweights the fact that rate risk is largely priced into the curve at 96% no-cut probability

→ vs conservative: Trimming 10-15% on a push toward $90-91 treats KO like a momentum stock when it's a 63-year dividend streak compounder with 0.34 beta—wrong playbook